102460 — Reyon Pharmaceutical Co Share Price
Last trade - 00:00- KR₩209bn
- KR₩403bn
- KR₩148bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.84 | ||
| Price to Tang. Book | 0.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.42 | ||
| EV to EBITDA | 73.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.05% | ||
| Return on Equity | 1.67% | ||
| Operating Margin | -0.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 130,034.15 | 142,801.37 | 154,038.84 | 151,071.14 | 148,299.67 | n/a | n/a | 2.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -33.25 | +41.77 | +28.51 | -51.44 | +22.91 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Company’s products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
Directors
- Su Cheon Park CEO (62)
- Sun Bong Ha VPR (59)
- Chung Wung Jang VPR (64)
- Gyu Sang Choi OTH (47)
- Seong Chang Hong OTH (68)
- Chang Yeol Park OTH (62)
- Yong Hwan Yoo OTH (38)
- Sun Ok Jung DRC (63)
- Jung Hyeop Kim NID (69)
- Seok Ho Lee NID (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 25th, 1964
- Public Since
- June 10th, 2010
- No. of Shareholders
- 23,643
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 18,340,991
- Address
- 43, Seobinggo-ro 91na-gil, Yongsan-gu, ANYANG, 14059
- Web
- https://reyonpharm.co.kr/
- Phone
- +82 314785304
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 102460
Similar to 102460
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 22:56 UTC, shares in Reyon Pharmaceutical Co are trading at KR₩11,450. This share price information is delayed by 15 minutes.
Shares in Reyon Pharmaceutical Co last closed at KR₩11,450 and the price had moved by -16.08% over the past 365 days. In terms of relative price strength the Reyon Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -15.12% over the past year.
There is no consensus recommendation for this security.
Find out moreReyon Pharmaceutical Co does not currently pay a dividend.
Reyon Pharmaceutical Co does not currently pay a dividend.
Reyon Pharmaceutical Co does not currently pay a dividend.
To buy shares in Reyon Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩11,450, shares in Reyon Pharmaceutical Co had a market capitalisation of KR₩209bn.
Here are the trading details for Reyon Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 102460
Based on an overall assessment of its quality, value and momentum Reyon Pharmaceutical Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Reyon Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.59%.
As of the last closing price of KR₩11,450, shares in Reyon Pharmaceutical Co were trading -14.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Reyon Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩11,450.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Reyon Pharmaceutical Co's management team is headed by:
- Su Cheon Park - CEO
- Sun Bong Ha - VPR
- Chung Wung Jang - VPR
- Gyu Sang Choi - OTH
- Seong Chang Hong - OTH
- Chang Yeol Park - OTH
- Yong Hwan Yoo - OTH
- Sun Ok Jung - DRC
- Jung Hyeop Kim - NID
- Seok Ho Lee - NID